patent.fyi
Applications  /  US 2026/0355158
United States Patent Application Publication

US 2026/0355158 A1

Published
Nov 12, 2026
Filed
Mar 16, 2026
Earliest date on the face
Feb 28, 2020
Classification
A61K 31/405
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Single-chain phosphocholine dispersion

What ifWhat if 1-arachidonoyl-glycero-phosphocholine served as the active ingredient in the oral liquid?
Claim language“6-bromotryptophan present in the oral composition”

The formulation disperses the phosphocholine in an aqueous vehicle with a nonionic emulsifier. A sealed unit-dose container holds a measured volume for swallowing.

1.1Larger volume dilute drink

What ifWhat if a 200 ml drink contained 6-bromotryptophan at 0.05 μg per ml?
Claim language“at least 0.1 μg per gram or per ml”

A buffered aqueous vehicle carries dissolved 6-bromotryptophan at the specified concentration. The full 200 ml serving supplies 10 μg, the same mass as 100 ml at 0.1 μg per ml.

1.2Rectal suppository release

What ifWhat if a rectal suppository released 6-bromotryptophan after insertion?
Claim language“formulated for oral administration”

Micronized 6-bromotryptophan is dispersed in a molded hard-fat base. The base melts at body temperature and releases the particles to dissolve in rectal fluid.

1.2Subcutaneous liquid delivery

What ifWhat if a prefilled syringe delivered 6-bromotryptophan into subcutaneous tissue?
Claim language“as an oral consumable composition”

The syringe contains a sterile, isotonic aqueous solution of 6-bromotryptophan. A short needle deposits a measured volume beneath the skin.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Oral liquid for simulated swallowing

A benchtop swallowing simulator uses an oral liquid containing 0.5 μg/mL of 6-bromotryptophan as a marker for sample recovery. An inlet syringe delivers the liquid onto a flexible tongue surface, and a motor drives the tongue through a programmed compression cycle. An outlet vial collects the transferred liquid, and liquid chromatography measures the recovered marker mass relative to the input mass.

Component substitution

Fluorinated tryptophan in oral solution

An oral solution uses 6-fluorotryptophan in place of 6-bromotryptophan. A calibrated pipette transfers an aqueous stock of 6-fluorotryptophan into a mixing vessel, and purified water brings the mixture to a final concentration of 0.5 μg/mL. Liquid chromatography against a 6-fluorotryptophan reference solution verifies the concentration before filling.

Parameter or scale variation

Two fill volumes at fixed content

Two oral liquid presentations contain 2 μg of 6-bromotryptophan per container. The smaller presentation contains 2 mL at 1 μg/mL, and the larger presentation contains 8 mL at 0.25 μg/mL. Separate vessels hold the two dilutions, and a calibrated volumetric filler dispenses each into its designated container.

Combination with existing systems

Oral liquid with a metering pump

A collapsible reservoir contains an oral solution with 0.5 μg/mL of 6-bromotryptophan and connects to a positive-displacement pump through a one-way inlet valve. The pump delivers 1 mL per full stroke through a capped dispensing tip into an oral measuring cup. Gravimetric checks use the measured liquid density to convert the mass dispensed per stroke into volume.

Oral liquid in dual-chamber packaging

A dual-chamber oral package holds 1 mL of a 5 μg/mL 6-bromotryptophan solution in one chamber and 9 mL of purified water in the other. Pressure on the water chamber opens a frangible seal between the chambers. The user inverts the sealed package to mix the contents, then opens the outlet to dispense the resulting 0.5 μg/mL oral solution.

Automated or data-driven variant

Automated gravimetric blending of oral liquid

A stock reservoir and a purified-water reservoir feed separate metering pumps connected to a mixing vessel on load cells. A controller uses the assayed stock concentration in μg/g and the target batch mass to calculate the stock mass required for a finished concentration of 0.5 μg/g of 6-bromotryptophan. The controller stops stock addition at the calculated mass, adds water to the target batch mass, and runs an agitator for the programmed mixing interval.

Specific version of a part

Concentration controlled by dilution

A measured volume of aqueous 6-bromotryptophan concentrate is diluted to a target of 0.20 μg per ml. Liquid chromatography with mass spectrometric detection verifies the concentration in the finished liquid.

Mass controlled powder sachet

A 1 g powder sachet contains 1 μg of 6-bromotryptophan, corresponding to 1 μg per gram. The active ingredient is blended with a small portion of maltodextrin before successive additions of the carrier distribute it through the batch.

Fast disintegrating chewable tablet

Mannitol forms the chewable matrix, and crospovidone promotes breakup on contact with saliva. Chewing fragments the tablet, and the dispersed material is swallowed.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 7,794,749 B2
Published
Sep 14, 2010
Filed
Aug 16, 2006
Class
A61K 9/22
Document BUS 2017/0340663 A1
Published
Nov 30, 2017
Filed
Jun 19, 2017
Class
A61K 33/08
Claim 1
Document A
Document B
1.16-bromotryptophan present in the oral composition in an amount of at least 0.1 μg per gram or per ml of the oral composition,
1.2wherein the oral composition is formulated for oral administration as an oral consumable composition.
The foregoing needs and other needs and objectives that will become apparent for the following description are achieved in the present invention which comprises the formulation of a rapidly dissolving solid oral dosage form for the delivery of a dietary supplement directed at increasing nitric oxide activity in the body of an individual, e.g. a human or an animal.
A · US 7,794,749 B2 · ¶ 8
The oral formulations and methods for use contemplate that the oral formulations are provided in a form suitable for oral administration, e.g., a tablet, a dissolvable tablet, a chewable tablet, a free-flowing powder, a capsule, a gelcap, or incorporated into a food (e.g., biscuit, treat, kibble or gummy).
B · US 2017/0340663 A1 · ¶ 35

An empty cell means only that no passage was reproduced there.

Statements in these documents
It is often desirable to achieve fast release of active compounds of solid oral dosage forms.
A · US 7,794,749 B2 · ¶ 3
The invention provides a method for reducing the disintegration time of a solid oral dosage form comprising biologically active ingredients directed at increasing nitric oxide activity.
A · US 7,794,749 B2 · ¶ 2
In another aspect, the invention provides a method for supplementing the diet of an animal, such as a human, equine, or other domesticated animal, in need thereof comprising administering to the animal the oral formulations as described and claimed herein.
B · US 2017/0340663 A1 · ¶ 4
In a related aspect, the oral formulations for dietary supplementation as described and claimed herein are provided as tablet, a dissolvable tablet, a chewable tablet, a free-flowing powder, a capsule, a gelcap or as part of a foodstuff.
B · US 2017/0340663 A1 · ¶ 5
Cite aspatent.fyi, US 2026/0355158 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355158/, SHA-256 f79eb3653573761ba3a055e06fb2ce9a8618d05da846555adeae22c51c41dcbc
First published
Permanent addresshttps://patent.fyi/US20260355158/
Content fingerprint (SHA-256)f79eb3653573761ba3a055e06fb2ce9a8618d05da846555adeae22c51c41dcbc
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi